Gensight Biologics : Redémarrage des AAC prévu en décembre - Financement nécessaire à CT
>Refinancement en cours de négociation - Gensight annonce une position de trésorerie de 3.4 M€ à fin septembre (vs 6.9 M€ à fin juin 2024) lui offrant une visibilité financière jusqu’à mi-novembre 2024. La reprise de la vente de Lumevoq au travers du programme d’autorisation d’accès compassionnel (AAC) en France est dorénavant prévue pour décembre vs novembre précédemment. La société est donc en cours de négociation d’un financement « relais » pour un « petit montant...GenSight Biologics is a clinical-stage biotechnology company based in France. Co. is engaged in discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system by combining a gene therapy-based approach with its core technology platforms of mitochondrial targeting sequence, or MTS, and optogenetics. Co.'s initial focus has been on developing therapies for severe retinal diseases, with the goal of preserving or restoring vision in patients suffering from sight-threatening ophthalmic diseases. Co.'s product pipeline comprises two candidates for the treatment of sight-threatening retinal degenerative diseases, GSO1O and GSO3O.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.